References

1. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Butkiewicz L, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Garcia JG, Guzman C, Jimeno J, Demetri GD.  Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues following failure of conventional chemotherapy.  J Clin Oncol, 2004;22:1480-1490. 
   
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Specific activating mutations in the epidermal growth factor receptor determine responsiveness of non-small cell lung cancer to Gefitinib.  New Eng J Med, 2004;350:2129-2139.
   
3. Grossman SA, Alavi JB, Supko JG, Carson KA, Priet R, Dorr A, Grundy JS, Holmlund. Efficacy and toxicity of an antisense oligonucleotide directed against protein kinase C-a (LY900003, ISIS 3521) delivered as a d1-day continuous intravenous infusion in patients with recurrent high grade astrocytomas.  Neuro-oncology, 2004;6:21-27. 
   
4. Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP.  Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.  Int. J. Cancer, 2004;113:490-498.
   
5. Supko JG, Alderson L, Wen P, Cassidy K, Pace S, Obrocea M, Hochberg F. Pharmacokinetics of gimatecan, an orally administered camptothecin analogue, in patients with malignant gliomas. Proc Am Soc Clin Oncol 2004;23:A2039.